Clinical Trials Logo

SARS-CoV-2 clinical trials

View clinical trials related to SARS-CoV-2.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06354998 Completed - SARS-CoV-2 Clinical Trials

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

Start date: April 8, 2024
Phase: Phase 3
Study type: Interventional

To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

NCT ID: NCT05903118 Completed - SARS-CoV-2 Clinical Trials

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

Start date: January 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.

NCT ID: NCT05897190 Completed - SARS-CoV-2 Clinical Trials

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

Start date: May 16, 2022
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

NCT ID: NCT05894590 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19.

NCT ID: NCT05894525 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation specified in COVID-19.

NCT ID: NCT05894499 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19 and explore risk factors.

NCT ID: NCT05882383 Completed - SARS-CoV-2 Clinical Trials

Changes of Optical Quality During the Peak of the Covid-19 Pandemic

Start date: November 25, 2022
Phase:
Study type: Observational

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

NCT ID: NCT05712096 Completed - COVID-19 Clinical Trials

eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services

VALOR C19 IL
Start date: March 9, 2023
Phase:
Study type: Observational

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EVUSHELD eligible patient population in the Clalit Health Services in Israel.

NCT ID: NCT05585632 Completed - Influenza Clinical Trials

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Start date: October 14, 2022
Phase: Phase 1
Study type: Interventional

The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.

NCT ID: NCT05477186 Completed - COVID-19 Clinical Trials

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Start date: August 12, 2022
Phase: Phase 1
Study type: Interventional

Prevention of COVID-19 caused by SARS-CoV-2.